Johnson & Johnson Receives FDA Clearance for Surgical Robot, Raises Dividend Recordedly
Johnson & Johnson (NYSE: JNJ) is experiencing strong performance in the stock market with a year-to-date gain of 28%, outpacing the S&P 500. The company reported second-quarter net sales of $25.3 billion, up 6.6% from last year and remains on track to exceed $100 billion in annual revenue for the first time in history as a biopharmaceutical firm. The healthcare giant recently received FDA clearance for its Ottava robotic-assisted surgery system, positioning itself in an underpenetrated market with potential long-term growth. Additionally, Johnson & Johnson has raised its dividend for 64 consecutive years, earning it the title of Dividend King. A major development is a proposed $5.5 billion settlement to resolve ongoing talc-related lawsuits, which could significantly reduce legal uncertainty and reputational damage. The company's strong free cash flow generation suggests this financial burden will not severely impact its operations.
Topics: dividend growth healthcare revenue guidance robotic surgery